ALKS-2680 is under clinical development by Synchronicity Pharma and currently in Phase I for Type 2 Narcolepsy (Narcolepsy without Cataplexy). According to GlobalData, Phase I drugs for Type 2 Narcolepsy (Narcolepsy without Cataplexy) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ALKS-2680 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ALKS-2680 overview

ALKS-2680 is under development for the treatment of narcolepsy (narcolepsy type 1, narcolepsy type 2) and idiopathic hypersomnia. The drug candidate acts by targeting orexin receptor type 2. it is administered through oral route.

It was under development for the treatment of disorders associated with excessive daytime sleepiness.

Synchronicity Pharma overview

Synchronicity Pharma discovers and develops novel therapies for the treatment of metabolic disorders, narcolepsy, and diabetes. The company has developed a proprietary platform which is designed to identify and characterize compounds that modulate the activity and function of molecular clocks and discovers drugs which modulate these clocks and clock-controlled systems. Synchronicity Pharma discovery programs include cryptochrome modulator programs and orexin modulator programs. The company conducts cryptochrome modulator programs to develop therapies for cushing’s syndrome and Type 2 diabetes; orexin modulator programs for narcolepsy and disorders associated with the excessive daytime sleepiness. It works in collaboration with Alkermes plc and Bay City Capital. Synchronicity Pharma is headquartered in San Francisco, California, the US.

For a complete picture of ALKS-2680’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.